Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Rainer Lothar Heuchel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2782-585X; OpenAlex author ID A5003411047. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 19

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. Genderized Gut and Oral Microbiome Shifts: Uncovering Sex-Specific Dysbiosis in Pancreatic Cancer Co-author DOI 10.1101/2024.10.02.616338↗
  3. The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells. Last author DOI 10.3390/ijms25179369↗
  4. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. Co-author DOI 10.1016/j.isci.2022.105317↗
  5. Cellular heterogeneity in pancreatic cancer: the different faces of gremlin action. Last author DOI 10.1038/s41392-022-01203-8↗
  6. Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium. Co-author DOI 10.1016/j.neo.2021.11.007↗
  7. 3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2021.101107↗
  8. Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models. Last author DOI 10.3389/fcell.2021.741162↗
  9. IL-17B/RB Activation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Metabolism and Growth. Co-author DOI 10.3390/cancers13215338↗
  10. Multimodal Imaging of Pancreatic Ductal Adenocarcinoma Using Multifunctional Nanoparticles as Contrast Agents. Co-author DOI 10.1021/acsami.0c15430↗
  11. Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.09.005↗
  12. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  13. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Co-author DOI 10.1002/1878-0261.12108↗
  14. Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics. First author DOI 10.1007/s11306-017-1199-6↗
  15. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Co-author DOI 10.1038/bjc.2017.140↗
  16. A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Co-author DOI 10.1097/cji.0000000000000164↗
  17. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2015.238543↗
  18. Desmoplasia and chemoresistance in pancreatic cancer. Co-author DOI 10.3390/cancers6042137↗
  19. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Co-author DOI 10.1016/j.stem.2011.10.001↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias J. Löhr · 16 shared papers, 2011–2024 · strength 1.82
  2. Beate Gündel · 3 shared papers, 2021–2024 · strength 0.57
  3. Carlos Fernández Moro · 5 shared papers, 2017–2024 · strength 0.54
  4. Dhifaf Sarhan · 2 shared papers, 2022–2024 · strength 0.33
  5. Caroline Sophie Verbeke · 5 shared papers, 2015–2019 · strength 0.30
  6. Aristidis Moustakas · 1 shared paper, 2022 · strength 0.26
  7. Daniela Wesch · 1 shared paper, 2026 · strength 0.24
  8. Rüdiger Braun · 1 shared paper, 2026 · strength 0.24
  9. Christoph Röcken · 1 shared paper, 2026 · strength 0.24
  10. Jan-Paul Gundlach · 1 shared paper, 2026 · strength 0.24
  11. Anna Maxi Wandmacher · 1 shared paper, 2026 · strength 0.24
  12. Anne‐Sophie Mehdorn · 1 shared paper, 2026 · strength 0.24
  13. Annika Bräuer · 1 shared paper, 2026 · strength 0.24
  14. Susanne Sebens · 1 shared paper, 2026 · strength 0.24
  15. Zara Ahmed Khan · 1 shared paper, 2024 · strength 0.21
  16. Margaret Chen · 1 shared paper, 2024 · strength 0.21
  17. Mikael Björnstedt · 1 shared paper, 2024 · strength 0.21
  18. Carina Strell · 2 shared papers, 2017–2021 · strength 0.18
  19. Xinyuan Liu · 1 shared paper, 2021 · strength 0.14
  20. Béla Bozóky · 1 shared paper, 2021 · strength 0.13
  21. Marco Gerling · 1 shared paper, 2021 · strength 0.13
  22. Benedek Bozóky · 1 shared paper, 2021 · strength 0.13
  23. JEFFREY Victor RAVETCH · 1 shared paper, 2022 · strength 0.12
  24. Mikael Karlsson · 1 shared paper, 2022 · strength 0.12
  25. Felix Popp · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.